Ipsen (Italy)

Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro

Tullio Florio, Stefano Thellung, Sara Arena et al. · European Journal of Endocrinology · 1999 · 81 citations

Life Sciences, Endocrinology, Cell Signaling +16

Efficacy of a slow‐release formulation of lanreotide (Autogel^® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study

Cristina L. Ronchi, Mara Boschetti, Ettore C. degli Uberti et al. · Clinical Endocrinology · 2007 · 69 citations

Pharmacy, Pharmacology, Pharmacotherapy +12

<b>Clinical results of long‐term slow‐release lanreotide treatment of acromegaly</b>

Massimo Giusti, E. Ciccarelli, D. Dallabonzana et al. · European Journal of Clinical Investigation · 1997 · 67 citations · Full text

Medicine, Endocrinology, Pharmacology +15

Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors

Emilio Bajetta, Giuseppe Procopio, Laura Catena et al. · Cancer · 2006 · 65 citations · Full text

Medicine, Oncology, Pharmacology +9

A somatostatin analogue inhibits MAP kinase activation and cell proliferation in human neuroblastoma and in human small cell lung carcinoma cell lines

Maria Grazia Cattaneo, D. Amoroso, Gualberto Gussoni et al. · FEBS Letters · 1996 · 60 citations · Full text

Life Sciences, Oncology, Pharmacology +14